Navigation Links
Contrast agent trials in swine
Date:10/16/2007

This release is available in German.

Mammography continues to be the method of choice for the early detection of breast cancer. However, because this technique is not as selective or specific as one would wish, and does not deliver reliable results for every level of tissue density, alternatives are being sought. Near-infrared fluorescence mammography, which works with rays of near-infrared (NIR) light instead of X-rays, is a highly promising techniquealthough effective contrast agents have thus far been lacking. A team led by John V. Frangioni at the Beth Israel Deaconess Medical Center of the Harvard Medical School in Boston, Massachusetts, has developed a contrast agent that makes visible the microcalcifications related to malignant breast tumors. The researchers report in the journal Angewandte Chemie that in validation trials in swine their new contrast agent distinguishes specific calcium salts in soft tissues, as well as depicting bones.

As breast cancer develops, calcium salts are deposited in breast tissue. These microscopic calcium deposits consist mostly of hydroxyapatite, a salt containing calcium and phosphate that is also present in bones.

As the basis of their NIR contrast agent, the researchers chose to use the osteoporosis drug pamidronate, a biphosphonate. Biphosphonates, which are also used for the treatment of bone metastases in breast cancer patients, preferentially bind to bone. Frangioni and his team attached a dye that both absorbs light and fluoresces in the NIR region of the spectrum to a pamidronate derivative. Light in this region of the spectrum penetrates especially well into living tissue without damaging it, and is also easy to detect.

Thanks to a simplified, reliable synthetic route to a new pamidronate derivative developed by Kumar R. Bhushan, the American team has now been able to synthesize large quantities of a contrast agent called Pam800enough to run a trial with large animals. Pigs are particularly well suited to such trials because their organs are of approximately the same size as human organs.

As confirmed by surgical incisions, intravenously administered Pam800 reveals the bones of pigs with very high sensitivity. When hydroxyapatite is injected into the soft tissues, the contrast agent marks only the tiny hydroxyapatite crystals with high selectivity and sensitivity. This could allow it to selectively reveal malignant abnormal tissue. The swine trials demonstrated that the use of real-time NIR fluorescence images even make possible image-guided surgery of the soft tissues and bones.


'/>"/>

Contact: John V. Frangioni
info@frangionilab.org
617-667-0692
John Wiley & Sons, Inc.
Source:Eurekalert

Related biology news :

1. Gadonanotubes greatly outperform existing MRI contrast agents
2. Got inexpensive contrast agent? Milk plays new role in imaging
3. New drug shows promise as powerful anticancer agent
4. To control germs, scientists deploy tiny agents provocateurs
5. Tiny avalanche photodiodes target bioterrorism agents
6. Software agents could help unmask reality of disease clusters
7. Mouse study: New muscle-building agent beats all previous ones
8. Chemical warfare agent detection technology used to treat lung disease
9. Trojan Horse agent halts bone metastasis in mice
10. Failed experiment yields a biocontrol agent that doesnt trigger antibiotic resistance
11. Gallium: A new antibacterial agent?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/12/2017)... DIEGO , Jan. 12, 2017  Trovagene, Inc. ... tumor DNA (ctDNA) technologies, today announced that it has ... Europe and the Middle East ... tests.  This milestone marks the first wave of international ... for urine and blood samples. The initial ...
(Date:1/11/2017)... , Jan. 11, 2017  Michael Johnson, co-founder of Visikol ... Capital Group, Inc., has been named to the elite "Forbes 30 ...  was one of 600 people in 20 fields nationwide to be ... of the 15,000 applicants were selected. ... He is currently a PhD candidate at Rutgers ...
(Date:1/4/2017)... , Jan. 4, 2017  For the thousands of attendees at ... global leader in connected health and biometric measurement devices and services, will ... On display in A&D Medical,s special CES Exhibit Suite ... the ongoing expansion of the company,s WellnessConnected product platform.  ... ...
Breaking Biology News(10 mins):
(Date:1/19/2017)... DUBLIN , Jan 19, 2017 Research ... Market by Profiling Technology, Biomolecules, Cancer Type, Application - Global Opportunity ... ... Report, forecasts that the global market is projected to reach $15,737 ... of 13% from 2016 to 2022. Omic technologies ...
(Date:1/19/2017)... and HOUSTON , ... ("NX Prenatal") today announced the formation of its ... leading clinicians and industry veterans who enhance the ... as it accelerates development of its novel prenatal ... provide medical, clinical and strategic guidance for the ...
(Date:1/19/2017)... Jan 19, 2017 Research and Markets ... has announced the addition of the ... - Forecast to 2025" report to their offering. ... The report provides a detailed analysis on current and future market ... 2025, using estimated market values as the base numbers ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... software to leading biopharmaceutical and medical device manufacturers and regulators, is proud to ... CFR Part 11-compliant email client designed to provide product vigilance departments with the ...
Breaking Biology Technology: